192 results on '"Abruzzo, Lynne V."'
Search Results
2. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia
3. LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients
4. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival
5. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification
6. Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status
7. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
8. Chromosomal abnormalities in Philadelphia chromosome–negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
9. Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
10. Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia
11. Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)
12. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia
13. Intricacies of CLL cytogenetic complexity
14. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib
15. Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events
16. Aberrant Methylation and Decreased Expression of NRIP1 in IGHV-Unmutated CLL
17. the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL
18. Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib
19. Synergy: karyotypes and mutations in CLL
20. The Genomic and Transcriptomic Landscape of Myeloid Sarcoma and Associated Acute Myeloid Leukemia
21. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens
22. Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS
23. Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients
24. MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS
25. Biological and Clinical Features of Patients with Chronic Lymphocytic Leukemia Bearing Trisomy 12
26. Myeloid Sarcoma of the Orbit and Ocular Adnexae
27. Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.
28. Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.
29. Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience
30. Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)
31. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
32. Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies
33. Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion,
34. Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS),
35. Cytogenetic Evolution (CE) In Patients (pts) with Low and Intermediate Risk Myelodysplastic Syndromes (MDS) Is Associated with Poor Prognosis
36. Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML).
37. Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes.
38. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience
39. Array CGH Analysis of Chronic Lymphocytic Leukemia Reveals Frequent Cryptic Monoallelic and Biallelic Deletions of Chromosome 22q11.
40. Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy.
41. Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patients with CLL Receiving Salvage Treatment.
42. De Novo Deletion 17p13.1 Chronic Lymphocytic Leukemia Shows Significant Clinical Heterogeneity: The MD Anderson/Mayo Clinic Experience.
43. The Natural History and Treatment Outcome of De-Novo Chromosome 17p Deletion CLL: A Single Institution Experience with 48 Patients.
44. High Blast Percentage, Chromosome 17 Abnormalities and Severe Pancytopenia Predict Death within Twelve Months in Patients with Myelofibrosis.
45. IgVH Mutational Status Does Not Affect Complete Remission Rate but Is Associated with Reduced Remission Duration in CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR)-Based Therapy.
46. Cytogenetic Findings and Pattern of Clonal Evolution Determine Survival in Patients with Primary or Secondary Myelofibrosis
47. Genomic Aberrations in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Count: Analysis of 1694 Patients.
48. CD20 Antigen Expression Is Increased in Trisomy 12 CLL as Compared to Other Cytogenetic Subtypes.
49. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
50. Secondary Leukemia after Imatinib Mesylate (IM) Therapy for Chronic Myelogenous Leukemia (CML).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.